

FIG. 1A




FIG. 1B

Only 21% of Patients Who Started Pirfenidone Remained on Full Dose After 2 Years




FIG. 2




FIG. 3




FIG. 4

LYT-100 Dose (mg TID)	Daily Dose (mg)	Parameter	Cohort	Lower Limit	Point Estimate	Upper Limit
450	1350	AUC _{24ss}	12A	0.746308317	0.795353433	0.847621644
450	1350	AUC _{24ss}	12B	0.781796432	0.818575161	0.857084103
450	1350	AUC _{24ss}	Pooled	0.776443094	0.805953306	0.83658511
450	1350	CMA _{Xss}	12A	0.490375293	0.531749175	0.576613848
450	1350	CMA _{Xss}	12B	0.515157044	0.565387983	0.620516745
450	1350	CMA _{Xss}	Pooled	0.516491704	0.551235434	0.588316331
500	1500	AUC _{24ss}	12A	0.829231464	0.883726036	0.941801827
500	1500	AUC _{24ss}	12B	0.868662703	0.909527956	0.95231567
500	1500	AUC _{24ss}	Pooled	0.862714549	0.895503674	0.929539011
500	1500	CMA _{Xss}	12A	0.544861437	0.590832416	0.640682053
500	1500	CMA _{Xss}	12B	0.572396715	0.62820887	0.68946305
500	1500	CMA _{Xss}	Pooled	0.573879671	0.612483816	0.653684812
550	1650	AUC _{24ss}	12A	0.91215461	0.97209864	1.035982009
550	1650	AUC _{24ss}	12B	0.955528973	1.000480752	1.047547237
550	1650	AUC _{24ss}	Pooled	0.948986004	0.985054041	1.022492913
550	1650	CMA _{Xss}	12A	0.59934758	0.649915658	0.704750259
550	1650	CMA _{Xss}	12B	0.629636387	0.691029758	0.758409354
550	1650	CMA _{Xss}	Pooled	0.631267638	0.673732198	0.719053294
600	1800	AUC _{24ss}	12A	0.995077757	1.060471244	1.130162192
600	1800	AUC _{24ss}	12B	1.042395243	1.091433548	1.142778804
600	1800	AUC _{24ss}	Pooled	1.035257459	1.074604408	1.115446814
600	1800	CMA _{Xss}	12A	0.653833724	0.7089989	0.768818464
600	1800	CMA _{Xss}	12B	0.686876058	0.753850645	0.827355659
600	1800	CMA _{Xss}	Pooled	0.688655605	0.734980579	0.784421775
650	1950	AUC _{24ss}	12A	1.078000903	1.148843847	1.224342375
650	1950	AUC _{24ss}	12B	1.129261513	1.182386343	1.238010371
650	1950	AUC _{24ss}	Pooled	1.121528914	1.164154776	1.208400715
650	1950	CMA _{Xss}	12A	0.708319868	0.768082141	0.83288667
650	1950	CMA _{Xss}	12B	0.74411573	0.816671532	0.896301964
650	1950	CMA _{Xss}	Pooled	0.746043572	0.796228961	0.849790256

FIG. 5

Extrapolated AUC and Cmax Comparisons for LYT-100 BID and TID dosing; % of pirfenidone at 801 mg TID

Dose	AUC24ss	CMAxss
450 mg TID	80.6%	55.1%
500 mg TID	89.6%	61.2%
550 mg TID	98.5%	67.4%
600 mg TID	107.5%	73.5%
650 mg TID	116.4%	79.6%
700 mg TID	125.4%	85.7%
850 mg TID	152.6%	104.1%
Dose	AUC24ss	CMAxss
700 mg BID	83.6%	85.7%
750 mg BID	89.6%	91.9%
800 mg BID	95.5%	98.0%
825 mg BID	98.5%	101.1%
850 mg BID	101.5%	104.1%
900 mg BID	107.5%	110.2%
950 mg BID	113.4%	116.4%
1000 mg BID	119.4%	122.5%

FIG. 6A

850 mg BID LYT-100 provides same AUC and Cmax of parent drug as 801 mg TID pirfenidone		
LYT-100 Dose	AUC	Cmax
850 mg BID	102% of pirfenidone @ 801 mg TID	104% of pirfenidone @ 801 mg TID

FIG. 6B

Adverse Events for LYT-100 (850 mg BID) vs. pirfenidone (801 mg TID)

System	LYT-100 (850 mg BID; n=35)		Pirfenidone (801 mg TID; n=37)	
Gastrointestinal	37.1% (13 events; 13 participants)		29.7% (13 events; 11 participants)	
Nervous	45.7% (19 events; 16 participants)		35.1% (17 events; 13 participants)	
Disorder	Fed	Fasted	Fed	Fasted
Nausea	11.4%	20.6%	8.1%	20%

FIG. 7




FIG. 8A

FIG. 8B




FIG. 8C

FIG. 8D




FIG. 9

Parent			
	C_{max} ($\mu\text{g/mL}$)	T_{max} (hr)	AUC_{0-24} ($\mu\text{g}\cdot\text{hr/mL}$)
LYT-100 550 mg TID (n = 21)	8.35 (45.8)	2.00 (1.00-4.00)	97.7 (63.0)
LYT-100 824 mg TID (n = 19)	12.2 (48.8)	1.00 (1.00-3.00)	146 (75.3)
Ratio (824/550) ^a	1.45 (39.5)	—	1.44 (60.8)
5-Carboxy Metabolite			
	C_{max} ($\mu\text{g/mL}$)	T_{max} (hr)	AUC_{0-24} ($\mu\text{g}\cdot\text{hr/mL}$)
LYT-100 550 mg TID (n = 21)	4.20 (40.3)	2.00 (1.00-4.00)	49.8 (59.1)
LYT-100 824 mg TID (n = 19)	5.48 (60.5)	2.00 (1.00-3.00)	71.7 (87.4)
Ratio (824/550) ^a	1.32 (36.5)	—	1.42 (63.4)

Stats shown as geometric mean (CV%) or Median (Min – Max) for Tmax

^a Ratio statistics are derived from subjects who received both treatments and had 24 hours of data for each treatment (n = 18)

FIG. 10A




FIG. 10B




FIG. 11




FIG. 12




FIG. 13




FIG. 14A




FIG. 14B




FIG. 15A





FIG. 15B



○ Cohort 12 △ Part 1 ● Part 2 □ Part 3





FIG. 17




Dot-dashed line shown at ratio of 1.5 for reference

FIG. 18

LYT-100 Dose (mg TID)	Cohort_Group	Point Estimate	Lower Limit	Upper Limit	BE achieved?
550	Cohort 12	0.985	0.949	1.022	Yes
	Part 1	1.064	0.991	1.141	Yes
	Part 2	0.866	0.831	0.901	Yes
	Pooled	0.956	0.926	0.986	Yes
687	Cohort 12	1.230	1.185	1.277	No
	Part 1	1.329	1.238	1.426	No
	Part 2	1.081	1.038	1.126	Yes
	Pooled	1.194	1.157	1.231	Yes
825	Cohort 12	1.478	1.423	1.534	No
	Part 1	1.595	1.487	1.712	No
	Part 2	1.298	1.247	1.352	No
	Pooled	1.434	1.390	1.479	No
962	Cohort 12	1.723	1.660	1.788	No
	Part 1	1.860	1.733	1.997	No
	Part 2	1.514	1.454	1.576	No
	Pooled	1.672	1.620	1.724	No
1100	Cohort 12	1.970	1.898	2.045	No
	Part 1	2.127	1.982	2.283	No
	Part 2	1.731	1.662	1.802	No
	Pooled	1.911	1.853	1.972	No

All predictions assume a pirfenidone reference dose of 801 mg TID

FIG. 19A



PK parameter predictions are illustrative only

FIG. 19B

LYT-100 Dose	AUC ₀₋₁₂	C _{max}
550 mg	0.956	0.764
825 mg	1.43	1.15

*vs pirfenidone 801 mg
TID

FIG. 20

Parameters	Placebo (N=85)	LYT-100 (N=92)	All Subjects (N=177)
Age (years) at Screening			
Mean	52.7	56.6	54.7
Age group n (%)			
< 65 years	67 (78.8)	69 (75.0)	136 (76.8)
>= 65 year	18 (21.2)	23 (25.0)	41 (23.2)
Sex n (%)			
Female	35 (41.2)	32 (34.8)	67 (37.9)
Male	50 (58.8)	60 (65.2)	110 (62.1)

FIG. 21

Parameters	Placebo (N=85)	LYT-100 (N=92)	All Subjects (N=177)
Ethnicity n (%)			
Hispanic or Latino	8 (9.4)	10 (10.9)	18 (10.2)
Not Hispanic or Latino	76 (89.4)	82 (89.1)	158 (89.3)
Not Reported	1 (1.2)	0 (0.0)	1 (0.6)
Race n (%)			
White	61 (71.8)	79 (85.9)	140 (79.1)
Asian	20 (23.5)	10 (10.9)	30 (16.9)
Black or African American	2 (2.4)	1 (1.1)	3 (1.7)
Other	2 (2.4)	2 (2.2)	4 (2.4)
Time from COVID diagnosis to first dose of study drug (days)			
Mean	58.1	56.3	57.1
SD	27.56	28.16	27.81
Median	57	51.5	54
Minimum	15	14	14
Maximum	127	125	127

FIG. 22

	Placebo N (%)	LYT-100 N (%)	All Subjects N (%)
Received At Least One Dose Of Study Drug	85 (100.0)	92 (100.0)	177 (100.0)
Completed Treatment Period Part A	74 (87.1)	73 (79.3)	147 (83.1)
Discontinued Treatment Period Part A	11 (12.9)	19 (20.7)	30 (16.9)
Reason For Premature Treatment Discontinuation			
Lost To Follow-Up	1 (1.2)	1 (1.1)	2 (1.1)
Physician Decision	0 (0.0)	1 (1.1)	1 (0.6)
Withdrawal of Consent	6 (7.1)	3 (3.3)	9 (5.1)
Adverse Event	3 (3.5)	11 (12.0)	14 (7.9)
Other	1 (1.2)	3 (3.3)	4 (2.4)
Completed Study Part A Enrolled in OLE	57 (67.1)	48 (52.2)	105 (59.3)

FIG. 23

	Placebo N (%)	LYT-100 N (%)	All Subjects N (%)
Number of subjects with at least one at least possibly related TEAE	2 (2.4)	8 (8.6)	10 (5.6)
Photosensitivity Reaction	0 (0.0)	2 (2.2)	2 (2.2)
Pruritus	0 (0.0)	1 (1.1)	1 (1.1)
Dyspepsia	1 (1.1)	1 (1.1)	2 (2.2)
Diarrhea	0 (0.0)	1 (1.1)	1 (1.1)
Liver Function Test Increased	0 (0.0)	1 (1.1)	1 (1.1)
Alanine Aminotransferase Increased	0 (0.0)	1 (1.1)	1 (1.1)
Hepatic Steatosis	0 (0.0)	1 (1.1)	1 (1.1)
Drug Hypersensitivity	0 (0.0)	1 (1.1)	1 (1.1)

FIG. 24A




FIG. 24B




FIG. 24C




FIG. 24D

Recent amendments to study protocol

- Allow prior exposure to nintedanib (<6 months)
- Allow use of nicotine except via smoking tobacco
- Remove upper age limit (age 40+)
- Allow patients with Child-Pugh A ([compensated] cirrhosis)
- Acknowledge open-label extension study that will be offered to patients who complete the 6-month study
- Will offer open label LYT-100 for a minimum of six months after the last patient enrolls
- Second HRCT at 6 months to look for differences in fibrosis progression

FIG. 25A**Patient Reported Assessment of IPF Symptoms**

-In the past 7 days.... on a scale from 0 to 4 (Never, Rarely, Sometimes, Often, Always),

how often did you have:

1. Shortness of breath?
2. Fatigue (physical exhaustion)?
3. Tiredness (mental exhaustion)?
4. Discomfort in the chest?
5. Loss of appetite?
6. Unexplained weight loss?

FIG. 25B**Patient Reported Assessment of Side Effects**

-In the past 7 days.... on a scale from 0 to 4 (Never, Rarely, Sometimes, Often, Always),

how often did you have:

1. Nausea?
2. Poor appetite?
3. Vomiting?
4. Belly discomfort?
5. Bloating?
6. Headache?
7. Tiredness (mental exhaustion)?
8. Fatigue (physical exhaustion)?
9. Feeling of no energy?
10. Dizziness?

-For each of items 1, 4-8, 10, and 12, at its worst, how bad was the symptom on a scale of 0-4 (Not bad at all, A little bad, Somewhat bad, Quite bad, Very bad)?

FIG. 26

Baseline Satisfaction

1. On a scale from 0 to 4 (Much Better, Moderately Better, A little better, No change), how much change in our IPF severity would you expect to see to be satisfied with IPF treatment?
2. On a scale from 0 to 4 (Not bad at all, A little bad, Somewhat bad, Quite bad, Very bad), how bad could side effects be for you to remain satisfied with an effective IPF treatment?
3. For each of the following, on a scale from 0 to 4 (Not bad at all, A little bad, Somewhat bad, Quite bad, Very bad), how bad could the following side effects be for you to remain satisfied with an effective IPF treatment?
 - a. Nausea?
 - b. Vomiting?
 - c. Reduced appetite?
 - d. Belly pain?
 - e. Belly discomfort?
 - f. Bloating?
 - g. Headache?
 - h. Mental exhaustion?
 - i. Physical exhaustion?
 - j. Tiredness?
 - k. No energy?
 - l. Fatigue?
 - m. Dizziness?

Overall Satisfaction

1. Considering your overall experience over the past 7 days, how satisfied are you with the study medication (on a scale from 0 to 6; Very satisfied, Moderately satisfied, A little satisfied, Neither satisfied nor dissatisfied, A little dissatisfied, Moderately dissatisfied, Very dissatisfied)?

FIG. 27

Metabolism of Pirfenidone and LYT-100 in the Presence of Individual CYP Isozymes

Compound	Metabolism Half-Life (t1/2) by CYP Isozyme (hr)		
	CYP1A2*	CYP2D6**	CYP2C19**
Pirfenidone	3.18 ± 0.11	2.13	2.30
LYT-100	9/08 ± 0.67	3.67	2.72

*Data represent Mean ± standard deviation for CYP1A2 (one lot of isozymes, tested in duplicate in two experiments)
**Data represent Mean for CYP2D6 and 2C1: one lot of isozymes, tested in duplicate in one experiment

FIG. 28

Overlay of Activity Results for LYT-100 and Pirfenidone in the BioMap Fibrosis Panel





FIG. 29






FIG. 31A




FIG. 31B




FIG. 32A





FIG. 32B



- ■ Group 4 (Saline/Vehicle, (1% CMC in MilliQ water) , Oral, QD) Treatment
- ⊕ ■ Group 5 (Bleo/Vehicle, (1% CMC in MilliQ water) , Oral, QD) Treatment
- ⊕ ■ Group 6 (Bleo/LYT-100, 400 mg/kg, Oral, QD) Treatment
- ⊕ ■ Group 7 (Bleo/Nintedanib, 60 mg/kg, Oral, BID) Treatment

FIG. 33A





FIG. 33B



- Group 4 (Saline/Vehicle, (1% CMC in MilliQ water), Oral, QD) Treatment
- Group 5 (Bleo/Vehicle, (1% CMC in MilliQ water), Oral, QD) Treatment
- ◆ Group 6 (Bleo/LYT-100, 400 mg/kg, Oral, QD) Treatment
- ⋈ Group 7 (Bleo/Nintedanib, 60 mg/kg, Oral, BID) Treatment




FIG. 35

Total Lung HP content (μg per left lung)

	Group 4 (Saline/Vehicle, (Saline) , Oral, QD) Treatment	Group 5 (Bleo/Vehicle, (Saline) , Oral, QD) Treatment	Group 6 (Bleo/LYT- 100, 400 mg/kg, Oral, QD) Treatment	Group 7 (Bleo/Nintedanib, 60 mg/kg,Oral, BID) Treatment
Number of Values	10	12	11	10
Mean	1276	2369	2203	1831
Std. Deviation	174.4	639.3	176.2	512.8
Std. Error of Mean	55.14	184.6	53.12	162.2
Coefficient of variation	13.67%	26.98%	7.997%	28.00%
T-test p Value Group 4 vs 5	–	<0.0001	–	–
T-test p Value Group 5 vs 6	–	–	0.4024	–

FIG. 36A





FIG. 36B



- ■ Group 4 (Saline/Vehicle, (1% CMC in MilliQ water) , Oral, QD) Treatment
- ■ Group 5 (Bleo/Vehicle, (1% CMC in MilliQ water) , Oral, QD) Treatment
- ■ Group 6 (Bleo/LYT-100, 400 mg/kg, Oral, QD) Treatment
- ■ Group 7 (Bleo/Nintedanib, 60 mg/kg, Oral, BID) Treatment

FIG. 37

	Group 4 (Saline/Vehicle, (Saline) , Oral, QD) Treatment	Group 5 (Bleo/Vehicle, (Saline) , Oral, QD) Treatment	Group 6 (Bleo/LYT- 100, 400 mg/kg, Oral, QD) Treatment	Group 7 (Bleo/Nintedanib, 60 mg/kg,Oral, BID) Treatment
Number of Values	10	12	11	10
Mean	2.838	4.453	3.724	3.872
Std. Deviation	0.3149	0.9325	0.4649	0.6235
Std. Error of Mean	0.09959	0.2692	0.1402	0.1972
Coefficient of variation	11.10%	20.94%	12.48%	16.10%
T-test p Value Group 4 vs 5	–	<0.0001	–	–
T-test p Value Group 5 vs 6	–	–	0.0202	–

FIG. 38A





FIG. 38B



- ◆ ■ Group 4 (Saline/Vehicle, (1% CMC in MilliQ water), Oral, QD) Treatment
- ◆ ■ Group 5 (Bleo/Vehicle, (1% CMC in MilliQ water), Oral, QD) Treatment
- ◆ ■ Group 6 (Bleo/LYT-100, 400 mg/kg, Oral, QD) Treatment
- * ■ Group 7 (Bleo/Nintedanib, 60 mg/kg, Oral, BID) Treatment

FIG. 38C






FIG. 38D



- ◆ ■ Group 4 (Saline/Vehicle, (1% CMC in MilliQ water), Oral, QD) Treatment
- ◆ ■ Group 5 (Bleo/Vehicle, (1% CMC in MilliQ water), Oral, QD) Treatment
- ◆ ■ Group 6 (Bleo/LYT-100, 400 mg/kg, Oral, QD) Treatment
- * ■ Group 7 (Bleo/Nintedanib, 60 mg/kg, Oral, BID) Treatment

FIG. 39



- Group 5 (Bleo/Vehicle, (1% CMC in MilliQ water) , Oral, QD) Treatment
- ◆ Group 6 (Bleo/LYT-100, 400 mg/kg, Oral, QD) Treatment
- * Group 7 (Bleo/Nintedanib, 60 mg/kg, Oral, BID) Treatment